CN117500773A - 在标记步骤期间制备具有低水含量的[18f]放射性标记化合物的方法 - Google Patents

在标记步骤期间制备具有低水含量的[18f]放射性标记化合物的方法 Download PDF

Info

Publication number
CN117500773A
CN117500773A CN202280043075.0A CN202280043075A CN117500773A CN 117500773 A CN117500773 A CN 117500773A CN 202280043075 A CN202280043075 A CN 202280043075A CN 117500773 A CN117500773 A CN 117500773A
Authority
CN
China
Prior art keywords
water content
fluoride
drying
during
acetonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280043075.0A
Other languages
English (en)
Chinese (zh)
Inventor
T·恩格尔
G·麦克罗比
A·克拉克
J·格里格
I·A·可汗
K·维克内
J·谢尔斯
A·杰克逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CN117500773A publication Critical patent/CN117500773A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280043075.0A 2021-06-16 2022-06-16 在标记步骤期间制备具有低水含量的[18f]放射性标记化合物的方法 Pending CN117500773A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2108605.3 2021-06-16
GBGB2108605.3A GB202108605D0 (en) 2021-06-16 2021-06-16 Effect of water content
PCT/EP2022/066483 WO2022263594A1 (en) 2021-06-16 2022-06-16 Method for preparing an [18f] radiolabelled compound with low water content during labelling step

Publications (1)

Publication Number Publication Date
CN117500773A true CN117500773A (zh) 2024-02-02

Family

ID=76954450

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280043075.0A Pending CN117500773A (zh) 2021-06-16 2022-06-16 在标记步骤期间制备具有低水含量的[18f]放射性标记化合物的方法

Country Status (12)

Country Link
US (2) US20240366808A1 (enExample)
EP (1) EP4355715A1 (enExample)
JP (1) JP2024522770A (enExample)
KR (1) KR20240021888A (enExample)
CN (1) CN117500773A (enExample)
AU (1) AU2022294052A1 (enExample)
BR (1) BR112023026514A2 (enExample)
CA (1) CA3223802A1 (enExample)
GB (1) GB202108605D0 (enExample)
IL (1) IL308917A (enExample)
MX (1) MX2023015076A (enExample)
WO (1) WO2022263594A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0520527D0 (en) 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
DK3323810T3 (da) 2010-02-08 2022-03-28 Lantheus Medical Imaging Inc Automatiseret reaktionssystem, kassette og indretning til syntese af billeddannelsesmidler
EP2657213A1 (en) * 2012-04-24 2013-10-30 Institut National de la Santé et de la Recherche Medicale Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
EP2880005B1 (en) * 2012-07-30 2016-05-25 Technical University of Denmark Radiofluorination method
CN107207379B (zh) * 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
EP3423113B1 (en) * 2016-02-29 2020-09-02 Oncodesign S.A. Radiolabeled macrocyclic egfr inhibitor
US11583596B2 (en) * 2017-09-26 2023-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Radiolabeled Darapladib and analogs thereof and their use as imaging compounds

Also Published As

Publication number Publication date
KR20240021888A (ko) 2024-02-19
US20240366808A1 (en) 2024-11-07
AU2022294052A1 (en) 2023-12-14
JP2024522770A (ja) 2024-06-21
WO2022263594A1 (en) 2022-12-22
IL308917A (en) 2024-01-01
MX2023015076A (es) 2024-01-18
CA3223802A1 (en) 2022-12-22
BR112023026514A2 (pt) 2024-03-05
GB202108605D0 (en) 2021-07-28
EP4355715A1 (en) 2024-04-24
US20250312494A1 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
EP2419096B1 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
JP7657759B2 (ja) 新規製剤及び合成方法
JP2023552180A5 (enExample)
US7018614B2 (en) Stabilization of radiopharmaceuticals labeled with 18-F
US20250312494A1 (en) Method for preparing an [18f] radiolabelled compound with low water content during labelling step
US20100228060A1 (en) Perfluoro-aryliodonium salts in nucleophilic aromatic 18f-fluorination
JP6446268B2 (ja) クエン酸緩衝液中の１８ｆ−フルシクロビン組成物
CN108794286A (zh) 使用具有羰基的醇溶剂生产氟化化合物的方法
Orlovskaya et al. Methods for the synthesis of fluorine-18-labeled aromatic amino acids, radiotracers for positron emission tomography (PET)
JP7424574B2 (ja) 放射性フッ素標識化合物の製造方法及び放射性医薬組成物の製造方法
US20240350683A1 (en) Preparation of a ph-adjusted ascorbic acid solution
JP5106118B2 (ja) 放射性フッ素標識有機化合物の製造方法
Huang et al. A two‐centre practical evaluation of [F‐18] FDOPA production methods and comparative dosimetry estimations based on in‐vivo microPET scans
US10695450B2 (en) Synthesis of a radioactive agent composition
WO2025114063A1 (en) Stabilized method for 18f-labeling
EP4559890A1 (en) Stabilized method for 18f-labeling
AU2010237040B9 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1167344A (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1167344B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1170672A (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1170672B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination